Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Pilomatrix-like High-Grade Endometrioid Carcinoma in the Female Genital Tract: A Single-Institution Clinicopathologic Analysis of 15 Cases.

Created on 13 Nov 2026

Authors

Na Mo, Ming Wang, Qiong Jin, Tong Wang, Shuli Yang, Haili Kang, Chunyan He, Xingzheng Zheng, Pingping Zhong, Yang Zhan, Yumei Wu, Yulan Jin

Published in

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. Pages 101116. Nov 12, 2026. Epub Nov 12, 2026.

Abstract

Pilomatrix-like high-grade endometrioid carcinoma (PiMHEC) is a rare endometrial neoplasm with incompletely defined diagnostic criteria and molecular pathogenesis. Clinicopathologic, immunohistochemical, and genomic features were analyzed in 15 PiMHEC cases: 14 uterine PiMHECs and 1 case with PiMHEC confined to an ovarian metastasis from a uterine low-grade endometrioid carcinoma (LGEC). All PiMHECs contained a dominant high-grade basaloid component (HGBC) with nested architecture and geographic necrosis; shadow cells were present in 12 of 15 cases. Concurrent LGEC (n=10) and atypical hyperplasia (n=6) were identified. The HGBC lacked ER, PR, and PAX8 expression, showed aberrant nuclear β-catenin accumulation, and expressed CD10 and CDX2 in all cases. CTNNB1 exon 3 mutations were detected in 13 cases; the remaining 2 CTNNB1-wildtype tumors harbored truncating APC mutations. PI3K/AKT pathway gene alterations were present in all cases and ARID1A alterations in 14 of 15 cases. Shared somatic mutations were identified in 4 paired HGBC and LGEC cases. Among 13 evaluable surgical specimens, metastases occurred with extensive lymphovascular space invasion (LVSI) in 60% (3/5), focal LVSI in 80% (4/5), and no LVSI in 33% (1/3). Outcomes differed by molecular subtype: 6/8 no specific molecular profile (NSMP) patients died within one year, whereas all seven deficient mismatch repair (dMMR) patients were alive at last follow-up. Two dMMR patients received immune checkpoint inhibitor (ICI)-containing regimens, with one durable response and one immune-mediated colitis-related discontinuation. These findings support PiMHEC derivation from an LGEC; the entity is characterized by Wnt/β-catenin pathway activation, with APC inactivation representing a potential novel alternative driver in CTNNB1-wildtype tumors. The differing outcomes between NSMP and dMMR tumors require cautious interpretation given the small cohort and ICI exposure in a subset of dMMR patients; nevertheless, ICI therapy warrants further evaluation in dMMR PiMHEC.

PMID:
43020431
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement